Mohanram et al. performed a post hoc analysis of the RENAAL study to investigate whether use of the angiotensin-receptor blocker losartan is associated with a reduction in hemoglobin level ...

The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...

In the main trial, BP fell by 30.2±18.5/16.6±10.1 and 29.1±19.2/16.8±10.1 mm Hg in the losartan and atenolol groups respectively. At the end of the follow-up, sitting systolic BP was reduced ...